-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, BeiGene announced that the Center for Drug Evaluation (CDE) of the National Food and Drug Administration (NMPA) of China has accepted its anti-PD-1 antibody drug Bezean (tislelizumab injection) for the treatment of the past New indication marketing application (sBLA) for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have progressed or become intolerable after receiving first-line standard chemotherapy
The marketing application for this new indication is based on the results of a randomized, open, multi-center global phase 3 clinical trial RATIONALE 302